Related Experiment Video
Updated: Jan 9, 2026
A Reversible, Non-invasive Method for Airway Resistance Measurements and Bronchoalveolar Lavage Fluid Sampling in Mice
Published on: April 13, 2010
Impact of Mepolizumab on Airway Remodeling and Inflammation in Severe Eosinophilic Asthma
Camille Taillé1, Fatima Hamidi2, Nicolas Heddebaut2
1Pneumology, Allergology and Transplantation Department, AP-HP, Hôpital Bichat, Paris, France; Inserm, Unit 1149, Université Paris Cité, Paris, France; Clinical Research Initiative in Severe Asthma: A Lever for Innovation & Science, Toulouse, France.
Background:
IL-5 is a key mediator of severe eosinophilic asthma (SEA) and also may contribute to airway remodeling.
Research Question:
Can mepolizumab, an anti-IL-5 antibody, modify airway remodelling in adult patients with SEA?
Study Design And Methods:
Thirty-seven patients who were eligible for mepolizumab were included prospectively. Mepolizumab 100 mg was administered subcutaneously every 4 weeks for 12 months. Bronchial biopsies and bronchoalveolar lavage (BAL) were performed at baseline, 6 months, and 12 months. Clinical and functional outcomes, airway remodeling, and inflammatory markers were assessed at each time point.
Results:
At 12 months, mepolizumab was shown to improve asthma control and FVC before bronchodilation and reduce the number of exacerbations, oral corticosteroid courses, and hospitalizations. These clinical and functional improvements were associated with a reduction in reticular basement membrane thickness (P < 0.0001), airway smooth muscle (ASM) mass (P = .0066), and proliferating cell nuclear antigen-positive ASM cells (P < .0001) in the bronchial mucosa at both 6 and 12 months. BAL fluid showed reduced levels of tenascin-C at 6 and 12 months and of fibulin-1 at 12 months. Blood eosinophil counts decreased significantly (P < .0001), and eosinophils were almost completely depleted in BAL fluid (P = .023) at 12 months. Submucosal eosinophilia was reduced to a lesser extent (P = .063).
Interpretation:
In addition to its antiinflammatory effects, mepolizumab also may attenuate structural airway changes in SEA, which could contribute to its clinical benefits.
Clinical Trial Registration:
ClinicalTrials.gov; No.: NCT03797404; URL: www.
Clinicaltrials:
gov.
Related Concept Videos
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:19Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:24Antiasthma Drugs: Methylxanthines
Theophylline is thought to inhibit phosphodiesterase enzymes, increasing intracellular levels of cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP). This rise in cAMP and cGMP concentrations stimulates cardiac function,...
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
01:17Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...